This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VRML vs. VNRX, MYMD, NAVB, MEIP, SGMO, BDTX, GLSI, MIST, ELDN, and PDEXShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include VolitionRx (VNRX), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), MEI Pharma (MEIP), Sangamo Therapeutics (SGMO), Black Diamond Therapeutics (BDTX), Greenwich LifeSciences (GLSI), Milestone Pharmaceuticals (MIST), Eledon Pharmaceuticals (ELDN), and Pro-Dex (PDEX). These companies are all part of the "medical" sector. Vermillion vs. Its Competitors VolitionRx MyMD Pharmaceuticals Navidea Biopharmaceuticals MEI Pharma Sangamo Therapeutics Black Diamond Therapeutics Greenwich LifeSciences Milestone Pharmaceuticals Eledon Pharmaceuticals Pro-Dex Vermillion (NASDAQ:VRML) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Which has more volatility & risk, VRML or VNRX? Vermillion has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Does the media refer more to VRML or VNRX? In the previous week, VolitionRx had 4 more articles in the media than Vermillion. MarketBeat recorded 4 mentions for VolitionRx and 0 mentions for Vermillion. VolitionRx's average media sentiment score of 0.15 beat Vermillion's score of 0.00 indicating that VolitionRx is being referred to more favorably in the news media. Company Overall Sentiment Vermillion Neutral VolitionRx Neutral Do analysts prefer VRML or VNRX? VolitionRx has a consensus price target of $3.50, indicating a potential upside of 433.46%. Given VolitionRx's stronger consensus rating and higher possible upside, analysts plainly believe VolitionRx is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, VRML or VNRX? Vermillion has higher revenue and earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVermillion$4.54M9.65-$15.24MN/AN/AVolitionRx$1.32M53.51-$35.32M-$0.25-2.62 Is VRML or VNRX more profitable? Vermillion has a net margin of -307.31% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Vermillion's return on equity.Company Net Margins Return on Equity Return on Assets Vermillion-307.31% -155.25% -103.47% VolitionRx -2,321.14%N/A -163.39% Do insiders & institutionals believe in VRML or VNRX? 18.1% of Vermillion shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 4.4% of Vermillion shares are held by company insiders. Comparatively, 10.4% of VolitionRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryVolitionRx beats Vermillion on 10 of the 16 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.81M$23.79M$5.79B$10.15BDividend YieldN/AN/A5.69%4.60%P/E Ratio-2.65N/A74.5925.92Price / Sales9.6519.95453.5485.33Price / CashN/AN/A37.0859.91Price / Book5.00N/A12.156.29Net Income-$15.24M-$19.12M$3.28B$270.77M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.45-1.1%N/A-50.4%$43.81M$4.54M-2.6543VNRXVolitionRx2.3255 of 5 stars$0.66-3.9%$3.50+427.7%-10.2%$71.36M$1.32M-1.8480Analyst ForecastGap UpMYMDMyMD PharmaceuticalsN/A$0.05-21.6%N/AN/A$114KN/A0.006Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010High Trading VolumeMEIPMEI Pharma1.3232 of 5 stars$4.85-0.2%N/A+5.6%$159.59MN/A-1.02100Upcoming EarningsGap UpSGMOSangamo Therapeutics2.5028 of 5 stars$0.54+3.7%$4.50+734.3%-37.0%$156.89M$57.80M-1.86480Positive NewsBDTXBlack Diamond Therapeutics3.5612 of 5 stars$2.80+1.8%$12.40+342.9%-45.0%$156.57MN/A12.1790Positive NewsGLSIGreenwich LifeSciences1.5371 of 5 stars$11.46-0.2%$42.00+266.5%-18.2%$156.48MN/A-8.433MISTMilestone Pharmaceuticals2.476 of 5 stars$1.84flat$5.00+171.7%+31.7%$156.39M$1M-2.1930News CoveragePositive NewsAnalyst ForecastELDNEledon Pharmaceuticals3.0142 of 5 stars$2.55-1.5%$10.00+292.2%-0.8%$155.09MN/A-2.1810News CoveragePositive NewsShort Interest ↓PDEXPro-Dex2.7156 of 5 stars$46.04-1.8%$56.00+21.6%+36.9%$152.88M$53.84M16.44140Positive News Related Companies and Tools Related Companies VolitionRx Competitors MyMD Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors MEI Pharma Competitors Sangamo Therapeutics Competitors Black Diamond Therapeutics Competitors Greenwich LifeSciences Competitors Milestone Pharmaceuticals Competitors Eledon Pharmaceuticals Competitors Pro-Dex Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
